1.
SAGE Open Med Case Rep
; 10: 2050313X221131863, 2022.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36388634
RESUMEN
Atezolizumab is a programmed cell death-ligand 1 antibody that modulates the immune system response and has shown great promise in treating malignancies. Cutaneous toxicities from immune checkpoint inhibitors are the most commonly reported immune-related adverse events, although toxicities related to immunotherapy are still being characterized. Herein, we present a novel case of inflamed actinic keratoses in a patient after receiving atezolizumab therapy that resolved without requirement of dose adjustment or discontinuation of treatment.
2.
3.
Dermatol Surg
; 48(7): 703, 2022 07 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-35510861
4.
J Am Acad Dermatol
; 85(6): e415-e416, 2021 12.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34437987